Dubai, UAE: Abdul Latif Jameel Health, part of international diversified family business Abdul Latif Jameel, is set to participate in Arab Health 2023, the epicenter of healthcare trade, taking place from January 30 to February 2, 2023 in Dubai, United Arab Emirates.

Abdul Latif Jameel Health will return to the 48th edition of Arab Health to showcase its portfolio of innovative technologies focused on accelerating the access to practical, affordable, and more inclusive healthcare solutions to help address the unmet demands across the emerging economies of the Global South.

As part of its participation, Abdul Latif Jameel Health will be joined by some of its renowned global partners, who will be presenting their technologies and hosting exciting talks at the Abdul Latif Jameel Health stand. These include:

  • Butterfly Network Inc. – The Butterfly iQ+TM is the world’s only single-probe, whole-body, handheld ultrasound device.
  • Holoeyes Inc. – Holoeyes Inc developed an innovative 3D virtual reality (VR) technology surgery support system and medical education software.
  • Melody International – Melody International has produced a unique medical instrument, the Mobile Fetal Monitor iCTG - Melody I, which is a small, smart, mobile fetal monitoring device.
  • Cyberdyne - Cyberdyne’s Hybrid Assistive Limb® – or HAL® – technology is the world’s first wearable cyborg-type robot exoskeleton.
  • Evelo Biosciences – Evelo Biosciences is developing an investigational oral medicine being for the treatment of inflammatory diseases.

The Abdul Latif Jameel Health team will also be joined by its Scientific Advisor Professor Charles Coombes, PhD MBBS FRCP MD FMedSci, Professor of Medical Oncology, Imperial College London, who is playing a key role in supporting the Company’s mission of accelerating access to modern medical care for those who need it most.

Akram Bouchenaki, Chief Executive Officer, Abdul Latif Jameel Health said: “We are looking forward to our participation at Arab Health 2023 and are keen to engage and network with industry peers who share our vision of a more accessible and equitable healthcare future. The ongoing disparity in access to modern medical care is one of our most pertinent modern-day challenges, and through partnerships and open dialogues, we can come together to deliver effective solutions to patients who need it most.”

Abdul Latif Jameel Health was founded in 2020 as a response to the ongoing global disparity in access to modern medical care and is focused on accelerating healthcare inclusion across fast growing markets and economies of the developing world. Abdul Latif Jameel Health is backed by Abdul Latif Jameel, one of the world’s most respected family businesses, and has partnered with some of the most innovative healthcare technology companies to fulfil its purpose to bring value to the communities in which it operates.

Visit Abdul Latif Jameel Health at Arab Health in Sheikh Saeed Hall 1, Stand S1.J10, Dubai World Trade Centre.

-Ends-

About Abdul Latif Jameel Health

Backed by Abdul Latif Jameel, one of the most respected diversified family businesses and investors with a 75-year heritage, deep roots, and established networks alongside a multi-sector presence in 30 countries across six continents, Abdul Latif Jameel Health is uniquely positioned as a trusted partner in realizing major innovations and opportunities in the healthcare world.

Abdul Latif Jameel Health reflects the Jameel family’s long-established commitment to innovating for a better future through Community Jameel, an international organization supporting science and technology-led solutions to global challenges.  Community Jameel and MIT co-founded the Abdul Latif Jameel Clinic for Machine Learning in Health (Jameel Clinic) in September 2018 – which has rapidly become the very epicenter of AI and healthcare at MIT – and the Abdul Latif Jameel Institute for Disease and Emergency Analytics (Jameel Institute) co-founded with Imperial College London, in October 2019, using novel data analytics to reduce global risk of preventable disease most recently including the 2020 COVID-19 pandemic, and strengthening health systems in the most fragile settings.

Abdul Latif Jameel Health takes this commitment into the commercial environment addressing tangible real-world needs today, for a better tomorrow.  It is focused on health care inclusion in the global south, accelerating access to modern medical care for those who need it most by opening up/growing new markets for distribution of existing solutions and investing in the future of MedTech.

The Jameel Investment Management Company (JIMCO) , actively invests in innovative, early-stage and breakthrough ventures and technology, aiming to positively shape the future of core industries driving the global economy through its’ investments that span medical and healthcare industries, from pharmaceuticals and vaccines to cutting-edge medical technology, along with emergent technologies across FinTech, InsurTech, electric vehicles and future mobility solutions.

For further information, visit: https://aljhealth.com and our brand video here.
Media Contact: Email aljhealth@edelman.com (GMT +4 hours UAE)

Copyright Notice and Disclaimer

© Meddist Company Ltd. (Abdul Latif Jameel Health).  All rights fully reserved.  The Abdul Latif Jameel name, and the Abdul Latif Jameel logotype and pentagon-shaped graphic are trademarks, or registered trademarks of Abdul Latif Jameel IPR Company Limited.

The term “Abdul Latif Jameel” refers broadly to several distinct, separate and independent legal entities. Abdul Latif Jameel is not itself a corporate entity, association or conglomerate run by an overarching parent company but merely refers to a group of distinct and wholly separate legal entities that are collectively referred to as Abdul Latif Jameel. Abdul Latif Jameel is not a corporate group as defined in section 1161(5) of the Companies Act 2006.

This document may contain forward-looking statements.  Forward-looking statements are statements regarding matters other than historical fact, such as future results, events, activities, developments or circumstances or the beliefs, plans or expectations of Abdul Latif Jameel Health or Abdul Latif Jameel entities or their respective managements.

Forward-looking statements often can be identified by the use of words such as ‘expect’, ‘project’, ‘anticipate’, ‘plan’, ‘estimate’, ‘believe’, ‘predict’, ‘intend’, ‘potential’, ‘possible’, ‘probable’, ‘likely’, ‘forecast’, ‘guidance’, ‘outlook’, ‘goal’, ‘target’, ‘may’, ‘will’, ‘should’ or ‘could’ or other similar terms or phrases.  However, the absence of such words does not mean that a particular statement is not forward looking.

Forward-looking statements are based on expectations and assumptions at the time of such statements and are subject to numerous risks and uncertainties, many of which are outside the control of Abdul Latif Jameel Health or Abdul Latif Jameel entities.  Should any of such expectations or assumptions prove incorrect, or should any of such risks or uncertainties materialize, actual future results, events, activities, developments or circumstances may differ materially from those expressed in or implied by forward-looking statements.

Further, any forward-looking statement speaks only as of the date on which it is made, and neither Abdul Latif Jameel Health nor Abdul Latif Jameel assumes, and hereby disclaims, any obligation to correct or update any forward-looking statement, whether as a result of new information, future events or otherwise.  All forward-looking statements made by Abdul Latif Jameel Health, Abdul Latif Jameel, or by any person on behalf of any of them, whether communicated in writing, electronically or orally, are qualified in their entirety by the foregoing cautionary statements. 

No Offer or Solicitation

This communication is not a proxy statement or solicitation of a proxy, consent or authorization with respect to any securities or in respect of the potential transaction and shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act, or an exemption therefrom.

For More Information, Please Contact:
Edelman
Muntaha Shaikh
aljhealth@edelman.com